Original Research J Clin Psychiatry February 2025

Brexpiprazole in Combination With Sertraline and as Monotherapy in Posttraumatic Stress Disorder: A Full-Factorial Randomized Clinical Trial

JCP 2025;86(1):10.4088/JCP.24m15577

Full Article Read the complete peer-reviewed article in J Clin Psychiatry. Clinical Summary PTSD remains chronic and disabling for many patients, and US Food and Drug Administration-approved pharmacologic options are limited to sertraline and paroxetine. In this trial, the clinically relevant question was whether adding brexpiprazole to sertraline improves PTSD symptoms beyond either agent alone. FAQ Did brexpiprazole added to sertraline improve PTSD symptoms in this trial?

Key Takeaways The efficacy signal was specific to the combination arm: brexpiprazole + sertraline improved CAPS-5 total score at Week 10 versus brexpiprazole + placebo by −4.24 (95% CI, −8.26 to −0.23; P=.038) and versus placebo + placebo by −5.99 (95% CI, −9.79 to −2.19; P=.0021), while neither monotherapy arm separated from placebo. Clinical Guide How do clinicians identify which adults with posttraumatic stress disorder are the best match for brexpiprazole plus sertraline based on this trial? Clinical Guide How should clinicians follow response and adverse effects when using brexpiprazole plus sertraline for posttraumatic stress disorder based on this trial?